Skip to content

Source filing unavailable

Q3 2025 · —
Revenue$0.00no prior Q3 2024 on fileno prior Q2 2025 on file
Net Income-$33.48Mno prior Q3 2024 on fileN/M vs Q2 2025
EPS Diluted-$21.66no prior Q3 2024 on fileN/M vs Q2 2025
Operating Income-$34,845,000—
Operating Cash Flowderived-$31,535,000—
Free Cash Flowderived-$31,628,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2024 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Parabilis Medicines, Inc. · CIK 1657677 · Engraved from SEC EDGAR